Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of SI-B001 + SI-B003 with or without chemotherapy in locally advanced or metastatic head and neck squamous cell carcinoma
CTR20223089Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Feb 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab, SI-B003, sponsored by Biokin Pharmaceutical. Started Feb 2023; status: active.
02
Drugs
izalontamabSI-B003
Beyond the preview
Go deeper on CTR20223089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223089.